Korea’s GC Labs Strengthens Middle East Presence

Press release

Published March 4th, 2022 - 12:50 GMT

Korea’s GC Labs Strengthens Middle East Presence

Eun-Hee Lee, President at GC Labs

Highlights

GC Labs is expanding their presence in the Middle East with new agreements signed with UAE based Life Diagnostics (Life Dx) and Precision Medical Laboratory (PML) from Jordan.

GC Labs, South Korea’s leading clinical laboratory, is expanding their presence in the Middle East with new agreements signed with UAE based Life Diagnostics (Life Dx) and Precision Medical Laboratory (PML) from Jordan.

Life Dx was already a partner for GC Labs in the UAE, and now with the new agreement, they will also collaborate with GC Labs in Oman, Saudi Arabia and Egypt.

Last month, the company also entered into an agreement with Bahrain clinical diagnostics laboratory Bio Lab, to provide services in the country.

Speaking about the new partnership agreements, Eun-Hee Lee, President at GC Labs, remarked: “There is strong regional demand for our laboratory testing services and, now with new and expanded agreements with our partners, we will be able to provide our services to more countries in the Middle East. Growing awareness of infectious diseases combined with government investments in healthcare, continue to drive demand for laboratory testing services in the region. We aim to support the regional sector with our advanced technology to deliver accurate diagnostics results with the lowest analytical uncertainty possible.”

More than 800 employees at GC Labs offer over 5,000 tests and test combinations, ranging from routine tests to highly esoteric molecular and genetic assays. According to GC Labs, Infectious disease, General Chemistry, and Metabolism tests are the most requested tests from the region.

To create a strong market leadership, GC Labs focuses on offering speedy Turn Around Time (TAT) with less error rate. The company also addresses the needs for precision in clinical diagnostics testing through active research and development. GC Labs has implemented a “Total Lab Automated” system to be able to achieve one of the shortest TAT, and the company is making further efforts to implement a Complete Lab Automated System.

Last year, GC Labs launched the “Infectious Disease Research Center”, which performs research on accuracy of diagnostic agents, establishing a model of surveillance system in response to emerging infectious diseases by using laboratory test data.

Throughout the year 2022, GC Labs plans to further expand its service agreements with partners in the region.

Background Information

GC Lab

GC Labs is the South Korea’s leading clinical laboratory, a specialist in infectious diseases, and serves as part of Global Diagnostics Network. GC Labs has enabled patients to receive accurate diagnoses and the right treatment with unrivaled quality of routine and specialized clinical tests. Around 800 employees at GC Labs offer more than 5,000 tests and test combinations, ranging from routine tests to highly esoteric molecular and genetic assays. With more than 35 years of accumulated know-how, GC Labs values the principles of providing the best treatment for patients even in unpredictable medical environments through passionate and ceaseless efforts. Not only domestically, but GC Labs has managed to expand overseas by entering a Lab Service Agreement with different countries such as Sri Lanka, Vietnam, Myanmar, Indonesia, India and UAE. GC Labs has excellent standard of medical manpower and infrastructure. For further information, please visit www.gclabs.co.kr/eng